Pemetrexed (Alimta)

Improvements in Radiation Therapies Give More Treatment Options

When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but[…]

Read More »

Giving Cediranib Another Chance

A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial[…]

Read More »

Pembrolizumab Update: Aduro Biotech Collaborates with Merck

A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYTRUDA ® treatment began to circulate late last year when data presented at the[…]

Read More »

Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients

The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to[…]

Read More »

The Latest Clinical Trial for Nintedanib – Are You a Candidate?

Scientists and researchers are excited over the latest completion of a Phase II clinical trial for those suffering from mesothelioma – an incurable asbestos-caused cancer that has a median survival of only 9 to 12 months.  The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma showed a slight[…]

Read More »

Ptac2S Potentially More Effective Than Cisplatin When Fighting Mesothelioma

Malignant Pleural Mesothelioma (MPM) is a rare, aggressive asbestos –related cancer that has a poor survival rate due to the fact that the cancer is hard to detect early, and once detected, has usually spread and is hard to control. Surgery is typically an effective option for removing cancerous cells,[…]

Read More »

Properties in Red Wine Could Help Fight Mesothelioma

Combining different types of treatment when it comes to treating mesothelioma is common because of how aggressive the cancer can be. While some treatments do prove to be effective, the overall prognosis of an individual with this asbestos-related cancer remains dim. A recent study done in Korea carefully evaluated the[…]

Read More »

Positive Genetic Studies and Treatment for Mesothelioma Patients

Understanding malignant mesothelioma and the way it develops is significant when discovering prevention, development control, and the eventual lead to a cure. Cancer researchers at the Mayo Clinic have been researching the genetic composition of the disease in hopes to find a connection between the development of mesothelioma and mutations[…]

Read More »

New mesothelioma treatment method may prolong the effectiveness of chemotherapy combination

Chemotherapy remains one of the most effective treatments for mesothelioma. Because there is no cure, it works to prolong the lives of patients. Unfortunately, even the most effective methods can become inadequate as treatments continue. A current clinical trial is attempting to extend the usefulness period of chemotherapy and in[…]

Read More »

Adding an inhibitor to mesothelioma treatment proves effective

A recent mesothelioma study found the addition of bevacizumab to the chemotherapy treatment of pemetrexed plus cisplatin may increase the survival rate in patients. From 2008 to 2014, patients were given the standard treatment in 21-day increments for six cycles, with some receiving bevacizumab. The addition of bevacizumab increased survival[…]

Read More »